title: Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis.
abstract: BACKGROUND
  To compare efficacy between recombinant human erythropoietin (rhEPO) plus parenteral iron vs. iron alone (parenteral vs. oral) in postpartum anaemia.
  
  
  METHODS
  Sixty patients (haemoglobin 8.6 +/- 1.1 g dL-1) were randomized to rhEPO plus intravenous (i.v.) iron sucrose (group 1), rhEPO placebo plus i.v. iron sucrose (group 2), or oral iron alone (group 3), daily for 4 days beginning 48-72 h postpartum. Erythropoiesis and iron status were assessed before, and on 4, 7 and 14 days after, starting therapy.
  
  
  RESULTS
  On day 7 the group 1 haematocrit increase was 7.7 +/- 3.1% vs. 5.3 +/- 1.9% (group 2, P < 0.01) and 4.4 +/- 3.2% (group 3, P < 0.01), and on day 14, 11.3 +/- 2.9% vs. 9.2 +/- 3.4% (group 2, P < 0.05) and 8 +/- 2.8% (group 3, P < 0.01). The odds of achieving a target haematocrit > 32% on day 7 and > 35% on day 14 were higher on rhEPO (1.5-2.7) than on either iron regimen alone. Group 1 reticulocyte counts were also higher on days 4 (P < 0.05 vs. oral iron) and 7 (P < 0.01 vs. oral and parenteral iron).
  
  
  CONCLUSIONS
  All three regimens were effective in postpartum anaemia, but the haematocrit and reticulocyte responses to rhEPO plus parenteral iron were significantly greater than to iron alone. Benefit was greatest in the blunted erythropoiesis subgroup with elevated post-Caesarean section C-reactive protein levels.
authors.affiliation: University of Zurich, Switzerland. christian.breymann@fhk.usz.ch
authors.forename: C
authors.initials: C
authors.lastname: Breymann
authors.forename: C
authors.initials: C
authors.lastname: Richter
authors.forename: C
authors.initials: C
authors.lastname: Hüttner
authors.forename: R
authors.initials: R
authors.lastname: Huch
authors.forename: A
authors.initials: A
authors.lastname: Huch
mesh_terms: D000740:Anemia / Q000188:drug therapy*; D002585:Cesarean Section; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination; D004906:Erythrocyte Count; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D019266:Iron, Dietary / Q000627:therapeutic use; D049590:Postpartum Period; D012156:Reticulocytes / Q000166:cytology; D013395:Sucrose / Q000627:therapeutic use
chemical_list: D019266:Iron, Dietary; D004921:Erythropoietin; D013395:Sucrose; D007501:Iron